J L Raoul
Overview
Explore the profile of J L Raoul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veziant J, Bouche O, Aparicio T, Barret M, El Hajbi F, Lepilliez V, et al.
Dig Liver Dis
. 2023 Aug;
55(12):1583-1601.
PMID: 37635055
Introduction: This document is a summary of the French intergroup guidelines regarding the management of esophageal cancer (EC) published in July 2022, available on the website of the French Society...
2.
Raoul J, Moreau-Bachelard C, Gilabert M, Edeline J, Frenel J
ESMO Open
. 2023 Feb;
8(1):100880.
PMID: 36764092
New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely...
3.
Raoul J, Faivre S, Frenel J, Rimassa L
Ann Oncol
. 2020 Feb;
30(1):6-8.
PMID: 32081277
No abstract available.
4.
Raoul J, Faivre S, Frenel J, Rimassa L
Ann Oncol
. 2018 Oct;
30(1):6-8.
PMID: 30358824
No abstract available.
5.
Bachet J, Lucidarme O, Levache C, Barbier E, Raoul J, Lecomte T, et al.
Eur J Cancer
. 2018 Oct;
104:108-116.
PMID: 30343254
Aim Of The Study: The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting....
6.
Thierry A, El Messaoudi S, Mollevi C, Raoul J, Guimbaud R, Pezet D, et al.
Ann Oncol
. 2017 Sep;
28(9):2149-2159.
PMID: 28911069
Background: While tumor-tissue remains the 'gold standard' for genetic analysis in cancer patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis from blood samples. Here,...
7.
Rochigneux P, Raoul J, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, et al.
Ann Oncol
. 2016 Dec;
28(4):809-817.
PMID: 27993817
Background: Use of chemotherapy near the end of life in patients with metastatic cancer is often ineffective and toxic. Data about the factors associated with its use remain scarce, especially...
8.
Metges J, Lebot M, Faroux R, Riaud F, Gamelin E, Capitain O, et al.
Oncologie (Paris)
. 2015 Jul;
16(5):267-276.
PMID: 26190928
Background: In 2006, bevacizumab, a targeted therapy agent was combined with FOLFIRI for the firstline treatment of patients with unresectable metastatic colorectal cancer. Methods/results: A study on a homogenous series...
9.
Araujo J, Bories E, Caillol F, Pesenti C, Guiramand J, Poizat F, et al.
Endosc Ultrasound
. 2014 Jun;
2(3):148-52.
PMID: 24949383
Objective: Endoscopic ultrasound (EUS) is established as the most accurate technique for pre-operative locoregional staging of gastroesophageal junction (GEJ) adenocarcinoma, the purpose of the present study was to evaluate the...
10.
Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Poree P, et al.
Eur J Nucl Med Mol Imaging
. 2013 Apr;
40(7):1057-68.
PMID: 23613103
Purpose: To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated...